Diagnostic and Therapeutic Radiopharmaceutical Agents for Selective Discrimination of Prostate Cancer
WASHINGTON STATE UNIV PULLMAN
Pagination or Media Count:
The project investigated the development of ligand linked Flutamide analogs for complexing a MCO3 Re,99mTc organometallic species to target prostate cancer for imaging and therapy. The project has been successful in developing and testing new synthetic strategies for this application. General methods were established for preparing the complexes in excellent yields95 at 10-4,10-5 M ligand concentration, testing the stability of the complexes pH, temperature and in vitro serum, AR - prostate cancer cells. First generation 99mTc flutamide analogs were examined. The results indicated the complexes formed with tridentate ligands i.e., cysteine, histidine were successfully prepared and maintained stability. The 21 approach analogs were prepared, however, failed to maintain the complex conformation, when examined under biological conditions. Second generation and addition coordination modes are also being investigated.
- Anatomy and Physiology
- Medicine and Medical Research